Danazol in non-splenectomized patients with refractory idiopathic thrombocytopenic purpura.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 2099421.
- Also identified by PMC identifier 2429727.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Seven non-splenectomized patients with chronic refractory idiopathic thrombocytopenic purpura were treated with danazol 800 mg daily. All were glucocorticoid failures and four were refractory to all additional previous therapy. Five patients benefited from danazol and in two sustained normal platelet counts, for over 44 and 51 months, were observed. We conclude that danazol is useful for long term management of otherwise refractory idiopathic thrombocytopenic purpura. The advantage of danazol over splenectomy as a first line treatment in steroid failure is suggested.
Medical subject headings
- Danazol
- Purpura, Thrombocytopenic